These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 4383150)

  • 1. Evidence for dopamine receptor stimulation by apomorphine.
    Andén NE; Rubenson A; Fuxe K; Hökfelt T
    J Pharm Pharmacol; 1967 Sep; 19(9):627-9. PubMed ID: 4383150
    [No Abstract]   [Full Text] [Related]  

  • 2. Pharmacological effects of 1,3-dimethyl-5-aminoadamantane, a new adamantane derivative.
    Maj J; Sowińska H; Baran L; Sarnek J
    Eur J Pharmacol; 1974 Apr; 26(1):9-14. PubMed ID: 4857604
    [No Abstract]   [Full Text] [Related]  

  • 3. Apomorphine and its effects on the spinal cord.
    Schlosser W; Horst WD; Spiegel HE; Sigg EB
    Neuropharmacology; 1972 May; 11(3):417-26. PubMed ID: 4340498
    [No Abstract]   [Full Text] [Related]  

  • 4. Effect of L-DOPA and analogues on central dopamine and noradrenaline mechanisms.
    Andén NE; Engel J
    Adv Neurol; 1974; 5():317-24. PubMed ID: 4613158
    [No Abstract]   [Full Text] [Related]  

  • 5. Adrenergic receptor blocking agents: effects on central noradrenaline and dopamine receptors and on motor activity.
    Andén NE; Strömbom U
    Psychopharmacologia; 1974; 38(2):91-103. PubMed ID: 4533319
    [No Abstract]   [Full Text] [Related]  

  • 6. Multiple receptors for brain dopamine in behavior regulation: concept of dopamine-E and dopamine-I receptors.
    Cools AR; van Rossum JM
    Life Sci; 1980 Oct; 27(14):1237-53. PubMed ID: 6255271
    [No Abstract]   [Full Text] [Related]  

  • 7. Effect of apomorphine, alpha-methylparatyrosine, haloperidol and reserpine on DOPA production in clonal cell lines (PC-12 and N1E-115).
    Bräutigam M; Laschinski G; Kittner B; Herken H
    Biochem Pharmacol; 1985 Apr; 34(7):941-7. PubMed ID: 3921032
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Central transmitter involvement in LON-954-induced tremorogenesis.
    Coward DM; Doggett NS; Thomas JE
    Neuropharmacology; 1977; 16(7-8):479-84. PubMed ID: 144244
    [No Abstract]   [Full Text] [Related]  

  • 9. Significance of dopamine receptor activity in dl-p-methoxyamphetamine- and d-amphetamine-induced locomotor activity.
    Tseng LF; Loh HH
    J Pharmacol Exp Ther; 1974 Jun; 189(3):717-24. PubMed ID: 4858403
    [No Abstract]   [Full Text] [Related]  

  • 10. Role of dopaminergic neurotransmission in locomotor stimulation by dexamphetamine and ethanol.
    Strömbom UH; Liedman B
    Psychopharmacology (Berl); 1982; 78(3):271-6. PubMed ID: 6296902
    [No Abstract]   [Full Text] [Related]  

  • 11. Hyperthyroidism: specifically increased response to central NA-(alpha-)receptor stimulation and generally increased monoamine turnover in brain.
    Strömbom U; Svensson TH; Jackson DM; Engström G
    J Neural Transm; 1977; 41(1):73-92. PubMed ID: 915501
    [No Abstract]   [Full Text] [Related]  

  • 12. Evidence for a new type of dopamine receptor stimulating agent.
    Corrodi H; Fuxe K; Ungerstedt U
    J Pharm Pharmacol; 1971 Dec; 23(12):989-91. PubMed ID: 4402038
    [No Abstract]   [Full Text] [Related]  

  • 13. Effect of neuroleptic drugs on central catecholamine turnover assessed using tyrosine- and dopamine- -hydroxylase inhibitors.
    Andén NE; Corrodi H; Fuxe K
    J Pharm Pharmacol; 1972 Mar; 24(3):177-82. PubMed ID: 4402775
    [No Abstract]   [Full Text] [Related]  

  • 14. Enhancement of reserpine-elicited dopaminergic supersensitivity by repeated treatment with apomorphine and alpha-methyl-p-tyrosine.
    Friedman E; Rotrosen J; Gurland M; Lambert GA; Gershon S
    Life Sci; 1975 Sep; 17(6):867-73. PubMed ID: 1238887
    [No Abstract]   [Full Text] [Related]  

  • 15. Release of dopamine from central noradrenaline nerves after treatment with reserpine plus amphetamine.
    Andén NE; Svensson TH
    J Neural Transm; 1973; 34(1):23-30. PubMed ID: 4714591
    [No Abstract]   [Full Text] [Related]  

  • 16. Influence of dopaminergic agonists and antagonists on serum prolactin concentrations in the rat.
    Horowski R; Gräf HJ
    Neuroendocrinology; 1976; 22(3):273-86. PubMed ID: 1028957
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Possible noradrenergic involvement in naloxone potentiation of apomorphine-induced stereotypic climbing in mice.
    Quock RM; Bloom AS; Sadowski JA
    Pharmacol Biochem Behav; 1984 Nov; 21(5):733-6. PubMed ID: 6096896
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pituitary follicle-stimulating hormone activity in rats treated with apomorphine, pimozide and drugs that modify catecholamine levels.
    Choudhury SA; Sharpe RM; Brown PS
    Neuroendocrinology; 1973; 12(4):272-83. PubMed ID: 4731030
    [No Abstract]   [Full Text] [Related]  

  • 19. Antischizophrenic drugs: chronic treatment elevates dopamine receptor binding in brain.
    Burt DR; Creese I; Snyder SH
    Science; 1977 Apr; 196(4287):326-8. PubMed ID: 847477
    [TBL] [Abstract][Full Text] [Related]  

  • 20. B-HT 958 stimulates dopamine autoreceptors but blocks noradrenaline autoreceptors in the brain.
    Grabowska-Andén M; Andén NE
    J Pharm Pharmacol; 1984 Nov; 36(11):748-52. PubMed ID: 6150978
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.